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Introduction
At present, no guidelines on the appropriate withdrawal of
ETN in JIA patients in clinical remission exist. The identi-
fication of predictors of clinical remission off medication
(CROM) in these patients represents the initial step in
their development.
Objectives
To evaluate the rate of CROM in JIA patients after ETN
withdrawal; to identify predictors of CROM in these
patients.
Methods
Retrospective data of polyarticular JIA patients who dis-
continued ETN due to clinical remission on therapy and
had a follow-up period after ETN withdrawal of at least
12 months were collected, including: age, number and
type of active joints at disease onset, sex, ANA status, dis-
ease duration before ETN start, number and type of active
joints, ESR, and CRP at the time of ETN start, duration of
clinical remission on medication and off-medication.
Based on their clinical course after ETN withdrawal,
patients were divided into 2 groups: 1) with CROM 2)
with disease flare. Demographic, clinical and laboratory
features were compared between the two groups.
Results
A total of 49 patients were included in the study. 11
patients (22,4%) achieved CROM, while 77.6% experi-
enced a disease flare after a median of 4,8 months (IQ
2.9-9.2). Patients with CROM showed a significantly
lower frequency of ANA positivity, ESR values < 20 mm/1
h and ankle involvement at the beginning of ETN treat-
ment than those who relapsed (respectively, p 0.034, 0.044
and 0.008). None of the other parameters showed any dif-
ference in the two groups.
Conclusion
Only 1/5 of JIA patients in our cohort achieved CROM.
Children with ANA negativity, ESR < 20 mm/1 h and
without ankle involvement have had a greater likelihood
of achieving CROM. Further prospective studies with
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